Mol. Cells 2002; 14(2): 163-167
Published online January 1, 1970
© The Korean Society for Molecular and Cellular Biology
NF-kB is a transcription factor that induces inflamma-tory cytokines and anti-apoptotic proteins. We de-signed a new NF-kB inhibitor that is based on the structure of the antibiotic epoxyquinomicin C. The designed compound, dehydroxymethyl-epoxyquino-micin (DHMEQ), inhibited the TNF-a-induced activa-tion of NF-kB, and showed an anti-arthritic effect in mice. Recently, we looked into its mechanism of inhibi-tion. DHMEQ inhibited the TNF-a-induced cellular DNA binding of nuclear NF-kB, but not the phos-phorylation or degradation of I-kB. Moreover, DHMEQ inhibited the TNF-a-induced nuclear accu-mulation of p65, a component of NF-kB. On the other hand, DHMEQ did not inhibit the nuclear transport of Smad2 and the large T antigen. Also, it did not inhibit the TNF-a-induced activation of JNK, but synergisti-cally induced apoptosis with TNF-a in human T cell leukemia Jurkat cells. Therefore, DHMEQ specifically inhibited the NF-kB-activating pathway in the TNF-a-treated cells. Taken together, our data show that DHMEQ is a unique inhibitor of NF-kB that acts at the level of the nuclear translocation. It may be useful as an anti-inflammatory and anticancer agent.
Keywords Apoptosis, DHMEQ, COS-1 Cells, NF-kB, Jurkat Cells
Mol. Cells 2002; 14(2): 163-167
Published online October 31, 2002
Copyright © The Korean Society for Molecular and Cellular Biology.
Kazuo Umezawa, Chanya Chaicharoenpong
NF-kB is a transcription factor that induces inflamma-tory cytokines and anti-apoptotic proteins. We de-signed a new NF-kB inhibitor that is based on the structure of the antibiotic epoxyquinomicin C. The designed compound, dehydroxymethyl-epoxyquino-micin (DHMEQ), inhibited the TNF-a-induced activa-tion of NF-kB, and showed an anti-arthritic effect in mice. Recently, we looked into its mechanism of inhibi-tion. DHMEQ inhibited the TNF-a-induced cellular DNA binding of nuclear NF-kB, but not the phos-phorylation or degradation of I-kB. Moreover, DHMEQ inhibited the TNF-a-induced nuclear accu-mulation of p65, a component of NF-kB. On the other hand, DHMEQ did not inhibit the nuclear transport of Smad2 and the large T antigen. Also, it did not inhibit the TNF-a-induced activation of JNK, but synergisti-cally induced apoptosis with TNF-a in human T cell leukemia Jurkat cells. Therefore, DHMEQ specifically inhibited the NF-kB-activating pathway in the TNF-a-treated cells. Taken together, our data show that DHMEQ is a unique inhibitor of NF-kB that acts at the level of the nuclear translocation. It may be useful as an anti-inflammatory and anticancer agent.
Keywords: Apoptosis, DHMEQ, COS-1 Cells, NF-kB, Jurkat Cells
Youngleem Kim, Dai-Wu Seol
Mol. Cells 2003; 15(3): 283-293 https://doi.org/10.14348/.2003.15.3.283Jae-Ho Chang, Yong-Suk Ryang, Tomohiro Morio, Sang-Kyou Lee, Eun-Ju Chang
Mol. Cells 2004; 18(2): 177-185 https://doi.org/10.14348/.2004.18.2.177Chaobing Ma, Xueyin Zu, Kangdong Liu, Ann M. Bode, Zigang Dong, Zhenzhen Liu, and Dong Joon Kim
Mol. Cells 2019; 42(9): 628-636 https://doi.org/10.14348/molcells.2019.0038